pharmaphorum

NOVEMBER 24, 2020

A merger involving two US digital health specialists and a blank cheque company has created a telemedicine player, called UpHealth, that is valued at more than $1.3 billion. The three-way deal combines UpHealth – which provides patient care management, telemedicine and digital pharmacy services and gives its name to the new group – with CloudBreak, which provides a video consultation platform for doctors and patients.

Packaging 138

Packaging Compounding Insurance Patient Care 138

Outsourcing Pharma

NOVEMBER 25, 2020

The new EU Pharmaceutical Strategy, adopted today by the European Commission, is designed to improve and accelerate patientsâ access to safe and affordable medicines and address unmet medical needs in the areas of antimicrobial resistance, cancer, and rare diseases.

97

97

Druggist

NOVEMBER 25, 2020

Citalopram is a popular antidepressant prescribed in the UK. It is also one of the most prescribed medicines in the UK. Although escitalopram is ‘related’ to citalopram, it significantly less prescribed. Today I will review differences between escitalopram and citalopram. Escitalopram vs citalopram, a summary of the post: Escitalopram vs citalopram: legal status.

Dosage 81

Dosage Hospitals 81

Pharma Mirror

NOVEMBER 24, 2020

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NS

FDA 52

FDA 52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

NOVEMBER 27, 2020

A new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children as young as six if they have specific gene mutations. The regulator has given a green light to use of Symkevi (tezacaftor/ivacaftor) with Vertex’ Kalydeco (ivacaftor) in patients ages six years and older who have two copies of the F508del mutation in the CFTR gene, or one F508del copy and one of 14 other so-called “minimal function” mutations in CFTR.

Labelling 134

Labelling FDA 134

Outsourcing Pharma

NOVEMBER 23, 2020

The pharma giant and the clinical-stage drug developer will join on a pilot study investigating a candidateâs potential in overcoming resistance of a cancer drug.

96

96

Pharma Mirror

NOVEMBER 21, 2020

The Hague — To help pharmacists advise people on COVID-19 tests, the International Pharmaceutical Federation (FIP), has today issued a guidance document. The guidance has been produced by FIP’s SARS-CoV-2 Testing Working Group, which has evaluated the diagnostic testing methods and devices currently available. The document covers how different types of diagnostic test work and the interpretation of results.

Documentation 52

Documentation Immunization 52

pharmaphorum

NOVEMBER 27, 2020

Amanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of the patient voice is stoking change in the rare disease space. New models of drug development are fuelling life-changing advantages in the rare disease space, previously an economic no-go area for pharma and biotech companies. That was among the discussion points during Fighting Rare Diseases – The Science, Economics and the Patients , a webinar hosted by o2h Group.

132

132

Outsourcing Pharma

NOVEMBER 24, 2020

The two companies will collaborate on a Phase III clinical trial investigating a potential treatment for patients hospitalized with COVID-19.

Hospitals 93

Hospitals 93

Med Ed 101

NOVEMBER 22, 2020

Working with geriatric patients and providers in primary care, I definitely have to stay up to date with regards to diabetes therapy. There have been a couple of diabetes updates in 2020 that I wanted to make sure you were aware of. The SGLT2 inhibitors is a class of medication that is undergoing a lot […]. The post Two Diabetes Updates in 2020 appeared first on Med Ed 101.

40

40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Mirror

NOVEMBER 21, 2020

Medisafe, a leading digital therapeutics company specializing in digital companions, has been selected by UCB to develop branded digital drug companions for its antiepileptic medications, with greater capabilities to expand across additional brands. The digital companions streamline support for patients to access financial assistance, patient diaries, and doctor discussion guides throughout their treatment journey.

52

52

pharmaphorum

NOVEMBER 23, 2020

Janssen’s Daniel de Schryver tells us why it’s time to give patients a permanent seat at the table and improve health outcomes through patient-pharma dialogue. I’m struck by just how much we thrive when we share a common purpose; when – as a society, a group or a family unit – we work together to achieve the same goal. It’s no different in healthcare.

Communication 128

Communication Documentation Vaccines 128

Outsourcing Pharma

NOVEMBER 23, 2020

The agency has given the go-ahead for use of baricitinib in conjunction with remdesivir for treating patients hospitalized with severe cases of the virus.

FDA 63

FDA Hospitals 63

Pharma Times

NOVEMBER 27, 2020

Tepotinib could be the first treatment on the market for NSCLC in adults harbouring METex14 skipping alterations

49

49

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Druggist

NOVEMBER 27, 2020

This year, clascoterone (brand name: Winlevi) has been approved by The United States Food and Drug Administration (FDA) for treatment of acne in the US. In the UK, there are several options for the management of acne, including topical preparations and oral antibiotics. In this post, I will review clascoterone and compare it to other treatments available in the UK.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98

pharmaphorum

NOVEMBER 25, 2020

An artificial intelligence tool developed by GE Healthcare twinned with a mobile X-ray device can help the placement of endotracheal tubes (ETTs), a necessary step for COVID-19 patients who require ventilation. The new tool – part of GE’s Critical Care Suite 2.0 – helps bedside staff and radiologists assess patients before intubation and make sure ETTs are positioned correctly which should reduce complications.

Hospitals 122

Hospitals 122

Outsourcing Pharma

NOVEMBER 24, 2020

Intelligent Tissue Group has launched its Intelligent Clinical trials facility to help assess the effectiveness and safety of potential new treatments.

53

53

Pharma Times

NOVEMBER 27, 2020

It is hoped that the test will help detect cancer at a much earlier stage

60

60

pharmaphorum

NOVEMBER 25, 2020

AstraZeneca’s research chief has said that the more effective dosing regimen of its coronavirus vaccine was discovered by accident. According to Reuters , the AstraZeneca development team made a minor mistake that made them realise they could significantly boost the success rate of the vaccine, codenamed AZD1222. Results announced earlier this week showed that by giving a half dose, followed by a full dose a month later, the vaccine’s efficacy could be boosted from 62% to around 90%.

Vaccines 119

Vaccines Compounding 119

pharmaphorum

NOVEMBER 25, 2020

Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition in the coming years, analysts have said. Following a briefing with management, a team of analysts led by Peter Welford said that the big Swiss pharma will be propped up by its psoriasis and infectious diseases blockbuster Cosentyx for some time.

Hospitals 119

Hospitals 119

pharmaphorum

NOVEMBER 24, 2020

Pharma sales is set to change forever. To keep afloat in the current climate, teams need to embrace flexibility and remember that traditional content won’t work in new contexts, say experts from Syneos Health. Selling in a socially-distanced world is about more than simply taking conversations online – it requires a wholesale change in how sales teams operate and the kinds of content they use.

Communication 119

Communication 119

pharmaphorum

NOVEMBER 25, 2020

Trio Health’s Neil McGregor-Paterson asks whether the healthcare industry has paid enough attention to the patient voice during COVID-19 and looks at the many ways pharma can improve the patient experience across the sector going forward. Never has the health and care voluntary sector (HCVS) played such a critical role in supporting our nation´s health and wellbeing.

Hospitals 115

Hospitals Vaccines 115

pharmaphorum

NOVEMBER 26, 2020

COVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products. But learning how to overcome the challenges of 2020 will serve the industry well for years to come. As part of our EU Leader series, Christian Pawlu, head of strategy, portfolio and BD&L at Sandoz, told us about how securing supply in a time of crisis will ensure future access, build resilience, and transform relationships.

Communication 111

Communication Pharmaceutical Companies Pharmaceutical Companies 111

pharmaphorum

NOVEMBER 24, 2020

The developer of Russia’s COVID-19 vaccine Sputnik V has pledged to make it available for less than $10 per dose – or $20 per two-dose course – on the same day as revealing new clinical data with the shot. Sputnik V ’s efficacy has remained high at 91.4% according to the latest analysis, which comes from almost 19,000 subjects who were assessed seven days after the second dose of the vaccine, administered 28 days after the first.

Vaccines 111

Vaccines Immunization 111

pharmaphorum

NOVEMBER 26, 2020

The UK’s pharma industry trade body has warned that Brexit could derail the government’s efforts to get coronavirus vaccines to the population, but welcomed other measures in this week’s spending review aimed at reviving the economy after the pandemic. In the build-up to chancellor Rishi Sunak’s announcement in the House of Commons, the Association of the British Pharmaceutical Industry (ABPI) chief executive Richard Torbett warned that a no-deal Brexit could disrupt supplies of vaccines.

Vaccines 105

Vaccines Packaging 105

pharmaphorum

NOVEMBER 26, 2020

BioNTech may be deeply ensconced in the latter stages of its bid to bring a COVID-19 vaccine to market, but it’s still pushing forward on other fronts, including a partnership with InstaDeep to deploy artificial intelligence and machine learning across its business. The two companies have been working together in this area since 2019, but BioNTech has opted to double down on the alliance with a revised agreement focusing on new immunotherapies for cancer and infectious diseases.

Vaccines 105

Vaccines Immunization 105

pharmaphorum

NOVEMBER 25, 2020

Pharmaceutical marketing budgets are going through a period of readjustment as companies explore and exploit a myriad of different digital channels to deliver content to, and engage with, their doctors and other audiences. The average allocation to digital channels with marketing budgets has doubled since 2016, up to 34% for 2020 according to Indegene research, and over a third of companies expect digital budget allocations to increase by more than 50% over the next three years.

105

105

pharmaphorum

NOVEMBER 23, 2020

AstraZeneca is preparing to file its COVID-19 vaccine with regulators after phase 3 trial results showed it is up to 90% effective. AZ made the announcemen t as the UK regulator reportedly gears up to make a decision on the rival vaccine from Pfizer and BioNTech, ahead of counterparts in the US and Europe. Results from trials conducted in the UK and Brazil showed an efficacy of 90% in 2,741 patients receiving the vaccine as a half dose, followed by a full dose at least one month apart.

Vaccines 105

Vaccines 105

pharmaphorum

NOVEMBER 26, 2020

AstraZeneca may have tried a positive spin on the trial mistake that led to the accidental discovery of the low dose COVID-19 vaccine regime with the highest efficacy– but the revelation has drawn a mixed response from commentators. The company’s share price has tumbled since the announcement of the trial results from AZD-1222 at the beginning of the week, reflecting an overall loss of confidence in the company’s handling of the trial.

Vaccines 98

Vaccines Immunization 98

pharmaphorum

NOVEMBER 23, 2020

German digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet age-related macular degeneration (AMD), a leading cause of blindness. The Munich-based company is launching the educational See What’s Next app in collaboration with Novartis, which sells the wet AMD medicines Beovu (brolucizumab) and Lucentis (ranibizumab), and has also been a big proponent of digital health technologies.

Communication 98

Communication 98

pharmaphorum

NOVEMBER 26, 2020

UK diagnostics firm Salient Bio has launched a robotics-driven COVID-19 mass testing platform after spinning out from Imperial College. The company says the technology is the fastest of its kind and can give results that are 99% accurate. There are a range of approaches to mass testing – with one group even suggesting that a breath test could be used and is planning trials of the device known as Microtox BT.

Vaccines 93

Vaccines 93

pharmaphorum

NOVEMBER 24, 2020

IQVIA’s Sarah Rickwood explores how pharma can help healthcare systems address treatment backlogs caused by the COVID-19 pandemic. As lockdowns started in the West during March 2020, there was, inevitably, much punditry on exit scenarios – for economies, populations, and healthcare systems. Considerable time was devoted to the discussion of V- , U- and L-shaped recoveries.

Pharmaceutical Companies 90

Pharmaceutical Companies Pharmaceutical Companies Vaccines Chemotherapy 90

pharmaphorum

NOVEMBER 25, 2020

Former chief digital officer for the NHS, Juliet Bauer, is now applying her experience to the private sector through video consultation firm Livi. She shares her thoughts on how well the NHS is integrating digital health and what the public and private sectors can do to further boost adoption. Bauer’s path to working in the NHS began when she spent many months in the care of the health service with a highly risky pregnancy and an extremely premature baby in NICU.

Hospitals 83

Hospitals 83

pharmaphorum

NOVEMBER 22, 2020

Rob Barker has been promoted to chief executive officer of Marlow, UK-based OPEN Health Group after serving as CEO of its Medical Communications practice for the last five years. He takes over as head of the healthcare communications group from co-founder David Rowley, who is stepping down after 10 years as CEO. Barker (pictured above) said: “I am excited to be leading such a talented and expert team who have been instrumental in growing OPEN Health to its current position.

Communication 80

Communication 80